Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CCCC

C4 Therapeutics Inc

4.06

Jul 10 • 04:00PM ET -0.23 (-5.36%)

Healthcare Biotechnology USA Small NASD

Peers: CHRS REPL ZNTL ALEC CLLS ELDN IMRX LENZ GLSI RZLT

| Held by: VTI IWM IWN VXF FESM IBB SCHA IWC DFAS PRFZ

Scroll to Statements

Index	RUT
Market Cap	448.90M
Enterprise Value	271.68M
Income	-103.80M
Sales	34.86M
Book/sh	2.25
Cash/sh	2.13
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	104
IPO	Oct 02, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	12.88
P/B	1.80
P/C	1.90
P/FCF	-
EV/EBITDA	-
EV/Sales	7.79
Quick Ratio	9.00
Current Ratio	9.00
Debt/Eq	0.25
LT Debt/Eq	0.22
Option/Short	Yes / Yes

EPS (ttm)	-1.18
EPS next Y	-1.01
EPS next Q	-0.21
EPS this Y	26.48%
EPS next Y	-7.94%
EPS next 5Y	1.38%
EPS past 3/5Y	21.55% 3.84%
Sales past 3/5Y	4.95% 1.61%
EPS Y/Y TTM	19.59%
Sales Y/Y TTM	-12.37%
EPS Q/Q	46.37%
Sales Q/Q	-15.00%
Earnings	May 12 BMO
EPS/Sales Surpr.	20.19% 40.38%

Insider Own	8.26%
Insider Trans	-0.11%
Inst Own	80.75%
Inst Trans	13.94%
ROA	-32.02%
ROE	-48.35%
ROIC	-36.27%
Gross Margin	77.73%
Oper. Margin	-295.77%
Profit Margin	-297.76%
SMA20	-2.68%
SMA50	8.26%
SMA200	47.41%
Trades

Shs Outstand	104.04M
Shs Float	101.44M
Short Float	24.64%
Short Ratio	7.92
Short Interest	25.00M
52W High	5.17 -21.47%
52W Low	1.69 140.22%
Volatility	10.50% 9.55%
ATR (14)	0.39
RSI (14)	49.66
Beta	2.90
Rel Volume	0.82
Avg Volume	3.15M
Volume	2,578,587

Perf Week	-5.58%
Perf Month	13.41%
Perf Quarter	43.46%
Perf Half Y	82.88%
Perf YTD	112.57%
Perf Year	104.02%
Perf 3Y	16.00%
Perf 5Y	-89.43%
Perf 10Y	-
Recom	1.14
Target Price	13.33
Prev Close	4.29
Price	4.06
Change	-5.36%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight	$8
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight	$6
Sep-04-25	Initiated	Guggenheim	Buy	$8
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$8 → $12
Nov-18-24	Initiated	Stephens	Equal-Weight	$4
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral	$6
Dec-13-23	Upgrade	Stifel	Hold → Buy	$2 → $12
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral	$12 → $10
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight	$15 → $5
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $15
Oct-11-22	Initiated	Morgan Stanley	Underweight	$6
Apr-28-22	Initiated	Credit Suisse	Underperform	$10
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$46 → $15
Mar-10-22	Initiated	JP Morgan	Overweight	$43
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$57
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$25
Nov-23-21	Initiated	BofA Securities	Buy	$54
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20
Sep-30-21	Initiated	Stifel	Hold	$45

Show Previous Ratings

Jun-11-26 07:00AM	C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population (GlobeNewswire)
May-20-26 07:00AM	C4 Therapeutics to Participate in Upcoming Conferences (GlobeNewswire) +5.47%
May-18-26 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.55%
May-12-26 07:00AM	C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-17-26 04:00AM	Roches DAC investment; Big Pharmas lavish CEO bumps (Pharma Voice)
06:10AM	Loading…
Apr-10-26 06:10AM	Roche and C4 Therapeutics to advance degrader-antibody conjugates research (Pharmaceutical Business Review) -10.42%
Apr-09-26 06:59AM	C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) (GlobeNewswire)
Mar-31-26 08:06PM	Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? (Quartz) +11.91%
Mar-25-26 07:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma (GlobeNewswire) +7.60%
Mar-09-26 08:11PM	C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data (Insider Monkey) +18.09% -13.09%
04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-07-26 12:26PM	C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference (MarketBeat)
Mar-06-26 12:00PM	Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice (Zacks)
Mar-05-26 09:40AM	Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:00AM	Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types (PR Newswire)
07:00AM	Loading…
Feb-26-26 07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-23-26 07:10AM	C4 Therapeutics to Participate in Upcoming March Conferences (GlobeNewswire) +6.48%
07:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-20-26 12:00PM	Strong Analyst Confidence in C4 Therapeutics (CCCC)'s Cemsidomide Drives 270% Upside Potential (Insider Monkey)
Feb-11-26 10:37PM	C4 Therapeutics Maps Cemsidomide Phase II Launch, BCMA Combo Plans at Guggenheim Conference (MarketBeat)
Feb-09-26 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-04-26 07:00AM	C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -5.97%
Feb-02-26 08:54PM	C4 Therapeutics, Inc. (CCCC): A Bull Case Theory (Insider Monkey) +6.91%
Jan-26-26 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-26 07:00AM	C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways (GlobeNewswire)
Dec-31-25 11:13AM	Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts? (Insider Monkey)
Nov-25-25 07:00AM	C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-06-25 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-04-25 08:35AM	Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates (Zacks) -8.87%
09:00AM	Loading…
Oct-17-25 09:00AM	Precision Oncology Approaches Drive $312B Market Transformation (PR Newswire)
Oct-16-25 07:08AM	C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering (GlobeNewswire) +11.71%
Oct-01-25 07:00AM	C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Sep-22-25 07:41AM	C4s multiple myeloma drug to reach pivotal trials after Phase I victory (Clinical Trials Arena) -17.41%
Sep-20-25 11:00AM	C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting (GlobeNewswire)
Sep-15-25 06:33PM	Why C4 Therapeutics Stock Crushed the Market on Monday (Motley Fool) +34.21%
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
Sep-04-25 07:00AM	C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration (GlobeNewswire)
Sep-03-25 07:00AM	C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting (GlobeNewswire)
Aug-12-25 08:00AM	Akamis Bio Announces the Appointment of Andrew Hirsch to the Companys Board of Directors (Business Wire) -7.44%
Aug-07-25 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +31.63%
07:00AM	C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-01-25 09:35AM	Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
May-07-25 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.38%
07:00AM	C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-25 05:15PM	Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Mar-03-25 09:35AM	C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.44%
Feb-27-25 09:35AM	C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-26-25 09:35AM	C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.02%
Feb-24-25 07:00AM	C4 Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Jan-14-25 07:00AM	C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology (GlobeNewswire) +6.86%
Jan-08-25 07:00AM	C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-25 09:55AM	Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Dec-30-24 02:48PM	Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-08-24 12:30PM	C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader (GlobeNewswire)
Nov-20-24 07:00AM	C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Nov-06-24 07:00AM	C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial (GlobeNewswire)
Nov-05-24 09:00AM	C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.58%
07:05AM	PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer (Business Wire)
Oct-31-24 08:20AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-28-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 04:01PM	C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. (GlobeNewswire) +7.14% +11.11%
Oct-09-24 07:00AM	C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit (GlobeNewswire)
Sep-30-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-24 10:00AM	C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-10-24 07:00AM	C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen (GlobeNewswire) +13.79%
Sep-08-24 06:05PM	C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-03-24 07:00AM	C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors (GlobeNewswire)
Aug-29-24 07:00AM	C4 Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 07:00AM	C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation (GlobeNewswire)
Aug-01-24 08:10AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-17-24 07:13AM	C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock? (Zacks) -7.05%
Jul-16-24 04:01PM	C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 (GlobeNewswire) +13.71%
Jul-09-24 12:00PM	C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why (Zacks) +12.87%
Jul-08-24 07:00AM	C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day (GlobeNewswire)
Jun-29-24 08:45PM	C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
Jun-10-24 07:00AM	C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors (GlobeNewswire)
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-10-24 02:52PM	C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations (GuruFocus.com) -9.41%
May-09-24 10:52AM	Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating (MT Newswires) +5.43%
May-08-24 02:53PM	C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates (MT Newswires) -5.01%
01:54PM	CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 07:00AM	C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum (GlobeNewswire)
Apr-08-24 08:00AM	C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-28-24 04:36AM	Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) (Insider Monkey)
Mar-05-24 04:30PM	C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 07:00AM	C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins (GlobeNewswire)
Feb-22-24 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +21.38%
07:36AM	C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-15-24 10:19AM	C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store? (Zacks) +8.07%
10:00AM	C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Jan-11-24 11:44AM	C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn (Zacks) -5.97%
Jan-09-24 06:20PM	C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +6.90% +5.77%

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in 2015 and is headquartered in Watertown, MA.

CEOMr. Andrew J. Hirsch M.B.A.

Ph.D.Dr. Kenneth C. Anderson M.D.

Principal Accounting OfficerMs. Kendra R. Adams

Chief Medical OfficerDr. Leonard M. J. Reyno M.D.

Co-Founder & Member of Scientific Advisory BoardDr. Nathanael S. Gray Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Kenneth Carl	Director	Jun 01 '26	Option Exercise	2.11	1,070	2,258	69,300	Jun 04 04:14 PM
Mark Mossler	Former Section 16 Officer	May 27 '26	Proposed Sale	3.91	9,087	35,485		May 28 08:31 PM
JOLIE M SIEGEL	Officer	Mar 09 '26	Proposed Sale	3.74	101,175	378,849		Mar 09 04:20 PM
REYNO LEONARD	Chief Medical Officer	Jan 16 '26	Sale	2.22	10,000	22,200	156,382	Jan 16 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CCCC

C4 Therapeutics Inc

Upgrade your Finviz experience